Tags

Type your tag names separated by a space and hit enter

Reduction of the severity of bronchial hyperresponsiveness by the novel leukotriene antagonist 4-oxo-8-[4-(4-phenyl-butoxy)benzoylamino]-2- (tetrazol-5-yl)-4H-1-benzopyran hemihydrate.
Arzneimittelforschung. 1994 Mar; 44(3):330-3.A

Abstract

There is much evidence that the cysteinyl-leukotrienes (C-LTs) are important in the pathogenesis of asthma. The clinical effect of a new leukotriene antagonist, ONO 1078 (4-oxo-8-[4-phenylbutoxy)benzoylamino]-2-(tetrazol-5-yl)-4H- 1-benzopyran hemihydrate, CAS 103177-37-3) on symptoms, pulmonary lung function and bronchial hyperresponsiveness was evaluated in patients with bronchial asthma. Eleven patients were treated for 24 weeks with 450 mg of ONO 1078 twice daily. The score of asthma symptom severity and the number of inhaled procaterol were significantly reduced after 2 weeks of ONO 1078 treatment and remained decreased for another 22 weeks. Their FEV1 and PC20 to histamine significantly improved 12 and 24 weeks after ONO 1078 treatment. The effectiveness of ONO 1078 suggests that the C-LTs play an important role in the pathogenesis of asthma. ONO 1078 might help to favorably modify the pathophysiologic condition in patients with bronchial asthma.

Authors+Show Affiliations

Second Department of Internal Medicine, Faculty of Medicine, University of Nagoya, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

7514876

Citation

Taki, F, et al. "Reduction of the Severity of Bronchial Hyperresponsiveness By the Novel Leukotriene Antagonist 4-oxo-8-[4-(4-phenyl-butoxy)benzoylamino]-2- (tetrazol-5-yl)-4H-1-benzopyran Hemihydrate." Arzneimittel-Forschung, vol. 44, no. 3, 1994, pp. 330-3.
Taki F, Suzuki R, Torii K, et al. Reduction of the severity of bronchial hyperresponsiveness by the novel leukotriene antagonist 4-oxo-8-[4-(4-phenyl-butoxy)benzoylamino]-2- (tetrazol-5-yl)-4H-1-benzopyran hemihydrate. Arzneimittelforschung. 1994;44(3):330-3.
Taki, F., Suzuki, R., Torii, K., Matsumoto, S., Taniguchi, H., & Takagi, K. (1994). Reduction of the severity of bronchial hyperresponsiveness by the novel leukotriene antagonist 4-oxo-8-[4-(4-phenyl-butoxy)benzoylamino]-2- (tetrazol-5-yl)-4H-1-benzopyran hemihydrate. Arzneimittel-Forschung, 44(3), 330-3.
Taki F, et al. Reduction of the Severity of Bronchial Hyperresponsiveness By the Novel Leukotriene Antagonist 4-oxo-8-[4-(4-phenyl-butoxy)benzoylamino]-2- (tetrazol-5-yl)-4H-1-benzopyran Hemihydrate. Arzneimittelforschung. 1994;44(3):330-3. PubMed PMID: 7514876.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reduction of the severity of bronchial hyperresponsiveness by the novel leukotriene antagonist 4-oxo-8-[4-(4-phenyl-butoxy)benzoylamino]-2- (tetrazol-5-yl)-4H-1-benzopyran hemihydrate. AU - Taki,F, AU - Suzuki,R, AU - Torii,K, AU - Matsumoto,S, AU - Taniguchi,H, AU - Takagi,K, PY - 1994/3/1/pubmed PY - 1994/3/1/medline PY - 1994/3/1/entrez SP - 330 EP - 3 JF - Arzneimittel-Forschung JO - Arzneimittelforschung VL - 44 IS - 3 N2 - There is much evidence that the cysteinyl-leukotrienes (C-LTs) are important in the pathogenesis of asthma. The clinical effect of a new leukotriene antagonist, ONO 1078 (4-oxo-8-[4-phenylbutoxy)benzoylamino]-2-(tetrazol-5-yl)-4H- 1-benzopyran hemihydrate, CAS 103177-37-3) on symptoms, pulmonary lung function and bronchial hyperresponsiveness was evaluated in patients with bronchial asthma. Eleven patients were treated for 24 weeks with 450 mg of ONO 1078 twice daily. The score of asthma symptom severity and the number of inhaled procaterol were significantly reduced after 2 weeks of ONO 1078 treatment and remained decreased for another 22 weeks. Their FEV1 and PC20 to histamine significantly improved 12 and 24 weeks after ONO 1078 treatment. The effectiveness of ONO 1078 suggests that the C-LTs play an important role in the pathogenesis of asthma. ONO 1078 might help to favorably modify the pathophysiologic condition in patients with bronchial asthma. SN - 0004-4172 UR - https://www.unboundmedicine.com/medline/citation/7514876/Reduction_of_the_severity_of_bronchial_hyperresponsiveness_by_the_novel_leukotriene_antagonist_4_oxo_8_[4__4_phenyl_butoxy_benzoylamino]_2___tetrazol_5_yl__4H_1_benzopyran_hemihydrate_ L2 - https://medlineplus.gov/asthma.html DB - PRIME DP - Unbound Medicine ER -